G
Gerardo Priotto
Researcher at World Health Organization
Publications - 29
Citations - 2641
Gerardo Priotto is an academic researcher from World Health Organization. The author has contributed to research in topics: African trypanosomiasis & Trypanosomiasis. The author has an hindex of 21, co-authored 28 publications receiving 2313 citations. Previous affiliations of Gerardo Priotto include Mbarara University of Science and Technology.
Papers
More filters
Journal ArticleDOI
Human African trypanosomiasis
TL;DR: Since patients are also reported from non-endemic countries, human African trypanosomiasis should be considered in differential diagnosis for travellers, tourists, migrants, and expatriates who have visited or lived in endemic areas.
Journal ArticleDOI
Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial
Gerardo Priotto,Serena Kasparian,Wilfried Mutombo,Daniel Ngouama,Sara Ghorashian,Ute Arnold,Salah Ghabri,Elisabeth Baudin,Vincent Buard,Serge Kazadi-Kyanza,Medard Ilunga,Willy Mutangala,Gabriele Pohlig,Caecilia Schmid,Unni Karunakara,Els Torreele,Victor Kande +16 more
TL;DR: The efficacy of NECT is non-inferior to that of eflornithine monotherapy, which is suitable for first-line use in HAT control programmes and potentially protective against the emergence of resistant parasites.
Journal ArticleDOI
Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo.
Gerardo Priotto,Serena Kasparian,Daniel Ngouama,Sara Ghorashian,Ute Arnold,Salah Ghabri,Unni Karunakara +6 more
TL;DR: The nifurtimox-eflornithine combination appears to be a promising first-line therapy for second-stage sleeping sickness and if corroborated by ongoing findings from additional sites (a multicenter extension of this study), will mark a major and multifaceted advance over current therapies.
Journal ArticleDOI
Validity, reliability and ease of use in the field of five rapid tests for the diagnosis of Plasmodium falciparum malaria in Uganda
TL;DR: The Paracheck Pf dipstick and device was considered as the most appropriate for the use in the field, being (97%), moderately specific, reliable, easy to use and cheap (about US$ 0.5/test).
Journal ArticleDOI
NECT is next: implementing the new drug combination therapy for Trypanosoma brucei gambiense sleeping sickness.
Oliver Yun,Gerardo Priotto,Jacqueline Tong,Laurence Flevaud,François Chappuis,François Chappuis +5 more
TL;DR: NECT stands as the most promising first-line treatment for second-stage T. gambiense HAT, based on the high efficacy and good safety profile observed in all studies done to date, against a background of recognized severity of stage 2 disease and toxicity of existing treatments.